Emergent BioSolutions Inc.
EBS
$5.08
$0.265.39%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -226.74% | 93.47% | 127.60% | 136.35% | 123.76% |
| Total Depreciation and Amortization | -6.81% | -11.67% | -11.95% | -12.54% | -11.14% |
| Total Amortization of Deferred Charges | 4,150.00% | 232.14% | 32.43% | -13.76% | -99.14% |
| Total Other Non-Cash Items | 944.71% | -86.33% | -21.62% | -51.52% | -109.46% |
| Change in Net Operating Assets | -77.75% | -34.07% | -125.25% | -187.50% | -119.68% |
| Cash from Operations | -42.19% | 34.42% | 190.63% | -92.38% | 119.48% |
| Capital Expenditure | 15.71% | 19.75% | 39.74% | 64.42% | 64.47% |
| Sale of Property, Plant, and Equipment | -99.57% | -99.78% | 383.54% | 406.58% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -100.00% | -- |
| Other Investing Activities | -167.20% | -63.64% | 50.00% | -- | 1,290.48% |
| Cash from Investing | -128.53% | -96.16% | -44.57% | 19.60% | 575.49% |
| Total Debt Issued | -33.56% | -- | -- | -100.00% | 157.65% |
| Total Debt Repaid | 36.44% | 76.24% | 76.68% | 98.62% | -222.15% |
| Issuance of Common Stock | -74.31% | -77.06% | -79.63% | -83.18% | 678.57% |
| Repurchase of Common Stock | -386.59% | -2,792.31% | -2,091.67% | -1,610.00% | -925.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -344.68% | -- | -- | 100.00% | 179.66% |
| Cash from Financing | 11.25% | 36.13% | 28.11% | 88.05% | -284.74% |
| Foreign Exchange rate Adjustments | -166.67% | 214.29% | -- | 106.67% | 175.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -165.05% | -88.21% | 1,796.72% | 35.28% | 1,236.36% |